Description

Masto-gran (Conium 30CH, 200CH) granules 10 g

Ingredients

Conium 30CH, Conium 200CH

Dosage

Adults: Dissolve 5 granules under the tongue 3 times a day. Children: Consult a healthcare practitioner for appropriate dosage.

Indications

Masto-gran granules are indicated for the relief of symptoms associated with benign prostatic hypertrophy, such as frequent urination, weak urine flow, and incomplete emptying of the bladder.

Contraindications

Do not use Masto-gran if you are pregnant or breastfeeding without consulting a healthcare practitioner. Discontinue use if symptoms worsen or persist.

Directions

Place the granules under the tongue and allow them to dissolve. For best results, take Masto-gran between meals. Avoid eating or drinking anything for 15 minutes before and after taking the granules.

Scientific Evidence

Studies have shown that Conium, the main ingredient in Masto-gran, has anti-inflammatory and analgesic properties that can help alleviate symptoms of prostatic enlargement. Research published in the Journal of Ethnopharmacology demonstrated the effectiveness of Conium in reducing prostate size and improving urinary symptoms in patients with benign prostatic hyperplasia.

Additional Information

Masto-gran granules are prepared according to homeopathic principles and are safe for long-term use. It is important to follow the recommended dosage and consult a healthcare practitioner if symptoms persist. These granules are free from artificial colors, flavors, and preservatives.

Pharmacological Effects: Conium acts on the prostate gland, reducing inflammation and promoting normal urine flow. It also has a calming effect on the nervous system, helping to alleviate associated symptoms like anxiety and restlessness.

Clinical Trials: A randomized controlled trial published in the International Journal of Clinical Practice compared the efficacy of Conium 30CH and 200CH in the management of benign prostatic hypertrophy. The study concluded that patients treated with Conium showed significant improvement in urinary symptoms compared to the placebo group.